LKYSF - DEA calls for increase in production of psychedelics for research - Marijuana Moment

The Drug Enforcement Agency ("DEA") is proposing to dramatically increase the legal production of psychedelic drugs to be used for research purposes, Marijuana Moment reports. The agency says in 2022, it is calling for a doubling of psilocybin and psilocyn production, a quadrupling of mescaline, and a quintupling of DMT. Notably, the DEA is suggesting an increase in the production of MDMA (ecstasy) from 50 grams this year to 3,200 grams next year. Marijuana production would also see a dramatic increase in the proposal: 3.2M grams next year up from 2M this year. A Federal Register notice set to publish on Oct. 18 notes that there has been a "significant increase" in use of hallucinogenic substances for research and clinical trials. Several companies, including COMPASS Pathways (CMPS -0.1%), MindMed (MNMD -0.6%), atai Life Sciences (ATAI +1.5%), Field Trip Health (FTRP +2.8%), Cybin (CYBN -5.4%), Seelos Therapeutics (SEEL -4.5%), and Numinus

For further details see:

DEA calls for increase in production of psychedelics for research - Marijuana Moment